Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Rocio Rosas-AlonsoJulian Colmenarejo-FernandezOlga PerniaCarlos Rodriguez-AntolínIsabel EstebanIsmael GhanemDario Sanchez-CabreroItsaso Losantos-GarciaSara Palacios-ZambranoGema Moreno-BuenoJavier de CastroVirginia Martinez-MarinInmaculada Ibañez de CáceresPublished in: Clinical epigenetics (2021)
We obtained similar results using both assays in the same cohort of patients, in terms of progression free survival and overall survival according to Kaplan-Meier curves. In addition, the results of ROC(t) curves showed that dp_qMSP increases the area under curve time-dependent in comparison with MSP for predicting progression free survival and overall survival over time. We concluded that dp_qMSP is an alternative methodology compatible with the results obtained with the conventional MSP. Our assay will improve the therapeutic management of glioblastoma patients, being a more sensitive and competitive alternative methodology that ensures the standardization of the MGMT-biomarker making it reliable and suitable for clinical use.